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Abstract
© 2017  APMIS.  Published  by  John  Wiley  &  Sons  Ltd  The  tumor-node-metastasis  (TNM)
classification, the presence of a mucinous component, and signet ring cells are well-known
criteria for identifying patients at a high risk for recurrence and determining the therapeutic
approach for early-stage colon cancer (eCC). Nevertheless, recurrence can unexpectedly occur
in some eCC cases after surgical resection. The aims of the present study were to evaluate the
relation of dysregulated MACC1, c-MET, and NM23-H1 expression with the histopathological
features of tumors in recurrence formation in eCC cases. A total of 100 sporadic eCC patients
without poor prognosis factors were evaluated in this  study.  The relationship between the
altered  expression  of  MACC1,  c-MET,  and  NM23-H1  and  pathological  microenvironmental
features,  including  the  presence  of  tumor  budding  and  desmoplasia,  were  assessed.  The
primary outcomes, including 5-year overall survival (OS) and disease-free survival (DFS), were
also measured. Compared with nonrecurrent patients, the expression level of MACC1 was 8.27-
fold higher, and NM23-H1 was 11.36-fold lower in patients with recurrence during the 5-year
follow-up (p = 0.0345 and p = 0.0301, respectively). In addition, the coexistence of high MACC1
and low NM23-H1 expression and tumor budding was associated with short OS (p < 0.001). We
suggest that the combination of reduced NM23-H1, induced MACC1, and the presence of tumor
budding are promising biomarkers for the prediction of recurrence and may aid the stratification
of patients with stage II colon cancer for adjuvant chemotherapy.
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